IPO registrations (S-1, F-1) · Registrants
Oruka Therapeutics, Inc.
- SEC CIK
- 907654 · filings on EDGAR ↗
- Former names
- ARCA biopharma, Inc. (2009–2024); NUVELO INC (2003–2009); HYSEQ INC (1997–2003)
- Registration
- Form S-1, first filed 1997-06-12, last 2024-11-14; 4 initial registrations, 10 amendments
- Outcome
- Final prospectus filed 1997-08-11; declared effective 2008-01-16; withdrawal requested 2021-04-02
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 855 OAK GROVE AVE., SUITE 100, Menlo Park, CA 94025
- EIN
- 36-3855489
- Ticker
- ORKA (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Oruka Therapeutics, Inc. on the corporate pages
On this site
- Form 5500 plan sponsor: ORUKA THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: ARCA biopharma, Inc. EXACT (CIK (EXACT))
- SEC filer: ARCA biopharma, Inc. EXACT (CIK (EXACT))
- Person page: Krishna Kittu Kolluri Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
- Person page: Raymond L Woosley Md Phd Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 80
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 1997-06-12 | S-1 | S-1 (registration) | HYSEQ INC | 0000950109-97-004525 ↗ |
| 1997-07-02 | S-1/A | S-1/A (amendment) | HYSEQ INC | 0001012870-97-001232 ↗ |
| 1997-07-17 | S-1/A | S-1/A (amendment) | HYSEQ INC | 0000898430-97-002939 ↗ |
| 1997-07-18 | S-1/A | S-1/A (amendment) | HYSEQ INC | 0000950109-97-005017 ↗ |
| 1997-07-29 | S-1/A | S-1/A (amendment) | HYSEQ INC | 0001017062-97-001378 ↗ |
| 1997-08-01 | S-1/A | S-1/A (amendment) | HYSEQ INC | 0001021408-97-000200 ↗ |
| 1997-08-04 | S-1/A | S-1/A (amendment) | HYSEQ INC | 0001012870-97-001389 ↗ |
| 1997-08-07 | S-1/A | S-1/A (amendment) | HYSEQ INC | 0000950109-97-005212 ↗ |
| 1997-08-07 | S-1MEF | S-1MEF (added securities) | HYSEQ INC | 0001012870-97-001487 ↗ |
| 1997-08-11 | 424B4 | 424B4 (final prospectus) | HYSEQ INC | 0001012870-97-001512 ↗ |
| 2008-01-16 | EFFECT | EFFECT (declared effective) | NUVELO INC | 9999999995-08-000162 ↗ |
| 2008-11-25 | EFFECT | EFFECT (declared effective) | NUVELO INC | 9999999995-08-003509 ↗ |
| 2011-04-04 | EFFECT | EFFECT (declared effective) | ARCA biopharma, Inc. | 9999999995-11-000880 ↗ |
| 2012-01-26 | EFFECT | EFFECT (declared effective) | ARCA biopharma, Inc. | 9999999995-12-000322 ↗ |
| 2013-02-14 | EFFECT | EFFECT (declared effective) | ARCA biopharma, Inc. | 9999999995-13-000533 ↗ |
| 2013-03-25 | S-1 | S-1 (registration) | ARCA biopharma, Inc. | 0001193125-13-124523 ↗ |
| 2013-04-04 | S-1/A | S-1/A (amendment) | ARCA biopharma, Inc. | 0001193125-13-142226 ↗ |
| 2013-05-15 | S-1/A | S-1/A (amendment) | ARCA biopharma, Inc. | 0001193125-13-222590 ↗ |
| 2013-05-24 | S-1/A | S-1/A (amendment) | ARCA biopharma, Inc. | 0001193125-13-233692 ↗ |
| 2013-05-29 | EFFECT | EFFECT (declared effective) | ARCA biopharma, Inc. | 9999999995-13-001653 ↗ |
| 2013-05-30 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-241556 ↗ |
| 2013-07-18 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-293224 ↗ |
| 2013-07-19 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-295775 ↗ |
| 2013-07-25 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-300803 ↗ |
| 2013-07-31 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-310609 ↗ |
| 2013-08-06 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-321693 ↗ |
| 2013-09-05 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-357252 ↗ |
| 2013-09-23 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-374839 ↗ |
| 2013-10-29 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-416194 ↗ |
| 2013-10-30 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-416378 ↗ |
| 2013-11-06 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-430449 ↗ |
| 2013-11-13 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-440411 ↗ |
| 2013-11-21 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-450003 ↗ |
| 2013-12-05 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-13-463659 ↗ |
| 2014-01-08 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-005525 ↗ |
| 2014-02-10 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-043451 ↗ |
| 2014-02-13 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-048514 ↗ |
| 2014-02-18 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-057221 ↗ |
| 2014-03-03 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-080635 ↗ |
| 2014-03-21 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-109060 ↗ |
| 2014-05-06 | EFFECT | EFFECT (declared effective) | ARCA biopharma, Inc. | 9999999995-14-001347 ↗ |
| 2014-05-14 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-197622 ↗ |
| 2014-06-09 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-230524 ↗ |
| 2014-08-14 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-308832 ↗ |
| 2014-08-18 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-313413 ↗ |
| 2014-11-12 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-409581 ↗ |
| 2014-12-02 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-429659 ↗ |
| 2014-12-10 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-439099 ↗ |
| 2014-12-11 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-440234 ↗ |
| 2014-12-30 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-14-457227 ↗ |
| 2015-02-05 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-15-033910 ↗ |
| 2015-02-17 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-000728 ↗ |
| 2015-02-23 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-000833 ↗ |
| 2015-03-16 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-001745 ↗ |
| 2015-03-19 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-001846 ↗ |
| 2015-04-13 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-002546 ↗ |
| 2015-04-14 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-15-129600 ↗ |
| 2015-05-12 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-004087 ↗ |
| 2015-06-05 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-004895 ↗ |
| 2015-06-11 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-005017 ↗ |
| 2015-06-11 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-005034 ↗ |
| 2015-06-23 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-005213 ↗ |
| 2015-07-16 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-005473 ↗ |
| 2015-07-20 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001193125-15-257115 ↗ |
| 2015-07-20 | EFFECT | EFFECT (declared effective) | ARCA biopharma, Inc. | 9999999995-15-001989 ↗ |
| 2015-08-11 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-007022 ↗ |
| 2015-09-03 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-007725 ↗ |
| 2015-09-09 | 424B4 | 424B4 (final prospectus) | ARCA biopharma, Inc. | 0001564590-15-007829 ↗ |
| 2015-10-26 | EFFECT | EFFECT (declared effective) | ARCA biopharma, Inc. | 9999999995-15-002865 ↗ |
| 2017-05-12 | EFFECT | EFFECT (declared effective) | ARCA biopharma, Inc. | 9999999995-17-001284 ↗ |
| 2020-02-26 | S-1 | S-1 (registration) | ARCA biopharma, Inc. | 0001193125-20-050219 ↗ |
| 2020-05-20 | EFFECT | EFFECT (declared effective) | ARCA biopharma, Inc. | 9999999995-20-001219 ↗ |
| 2021-03-30 | EFFECT | EFFECT (declared effective) | ARCA biopharma, Inc. | 9999999995-21-001215 ↗ |
| 2021-04-02 | RW | RW (withdrawal request) | ARCA biopharma, Inc. | 0001193125-21-105226 ↗ |
| 2024-07-24 | EFFECT | EFFECT (declared effective) | ARCA biopharma, Inc. | 9999999995-24-002258 ↗ |
| 2024-11-14 | S-1 | S-1 (registration) | Oruka Therapeutics, Inc. | 0001213900-24-097737 ↗ |
| 2024-11-26 | EFFECT | EFFECT (declared effective) | Oruka Therapeutics, Inc. | 9999999995-24-003588 ↗ |
| 2025-03-11 | EFFECT | EFFECT (declared effective) | Oruka Therapeutics, Inc. | 9999999995-25-000640 ↗ |
| 2026-04-10 | EFFECT | EFFECT (declared effective) | Oruka Therapeutics, Inc. | 9999999995-26-001154 ↗ |
| 2026-08-27 | EFFECT | EFFECT (declared effective) | Oruka Therapeutics, Inc. | 9999999995-26-002787 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| LOVE TED W | Director; Director,Officer | C.E.O; C.E.O.; President and C.E.O. | 8 | 2006–2010 | |
| GAVIN JAMES R III | Director | 5 | 2006–2008 | ||
| PENDERGAST MARY K | Director | 5 | 2006–2010 | ||
| Popovits Kimberly J | Director | 3 | 2006–2008 | ||
| ZUBROW BARRY L | Director | 2 | 2006–2007 | ||
| PERRY MARK L | Director | 4 | 2006–2008 | ||
| SOBEL BURTON E | Director | 11 | 2006–2012 | ||
| Wolff Henry Ward | Officer | Sr. VP Finance and CFO | 3 | 2006–2007 | |
| BENDEKGEY E LEE | Officer | CFO and Treasurer; Sr. VP CFO and General Counsel; Sr VP & General Counsel | 4 | 2006–2009 | |
| LEVY MICHAEL D | Officer | Executive Vice President; Sr. VP Research & Development | 3 | 2006–2008 | |
| Titus Gary | Officer | Chief Acct.Officer; VP Finance, Chief Acct.Officer | 5 | 2006 | |
| Atlas Venture Associates VII, L.P. | TenPercentOwner | 2 | 2009–2012 | ||
| Atlas Venture Fund VII L P | TenPercentOwner | 3 | 2009–2012 | ||
| BOULDER VENTURES IV ANNEX LP | TenPercentOwner | 2 | 2009 | ||
| BOULDER VENTURES IV LP | TenPercentOwner | 2 | 2009 | ||
| BREWER RICHARD B | Director; Director,Officer | President and CEO | 3 | 2009–2012 | |
| BRISTOW MICHAEL R | Director,Officer; Director,Officer,TenPercentOwner | Chief Science and Med. Officer; Pres & CEO; Pres. & Chief Executive Offic; President and CEO; See Remarks | 24 | 2009–2021 | |
| BV PARTNERS IV, L.L.C. | TenPercentOwner | 2 | 2009 | ||
| Fidler Josh E | TenPercentOwner | 2 | 2009 | ||
| FORMELA JEAN FRANCOIS | Director; Director,TenPercentOwner | 6 | 2009–2012 | ||
| FREYTAG J WILLIAM | Director | 3 | 2009–2010 | ||
| Grais Linda | Director | 15 | 2009–2024 | ||
| JONES ANDREW E | TenPercentOwner | 2 | 2009 | ||
| LEFKOFF KYLE | TenPercentOwner | 2 | 2009 | ||
| Lowe David George | Director; Director,TenPercentOwner | 6 | 2009 | ||
| Macks Lawrence M | TenPercentOwner | 2 | 2009 | ||
| Ozeroff Christopher David | Officer | EVP & General Counsel; SVP and General Counsel; S.V.P., General Counsel; SVP & GENERAL COUNSEL | 20 | 2009–2021 | |
| Roshko Peter | TenPercentOwner | 2 | 2009 | ||
| Skyline Venture Partners Qualified Purchaser Fund IV L P | Other; TenPercentOwner | 4 | 2009 | ||
| St Laurent Randall | Officer | EVP Commercial Operations | 1 | 2009 | |
| ZABRISKIE JOHN L | Director | 7 | 2009–2013 | ||
| FALBERG KATHRYN E | Officer | CFO and COO | 4 | 2009 | |
| Wheeler Patrick M | Officer | Acting CFO; acting Chief Financial Officer; Chief Financial Officer | 6 | 2009–2014 | |
| Woosley Raymond L. | Director | 10 | 2013–2024 | person page Fuzzy | |
| CONWAY ROBERT E | Director; Director,Other; DirectorOther | 18 | 2013–2024 | ||
| mccormack riley | TenPercentOwner | 4 | 2013–2015 | ||
| MITCHELL DANIEL J | Director | 9 | 2014–2024 | ||
| Keuer Thomas A | Officer | Chief Operating Officer | 17 | 2014–2022 | |
| Selby Brian L. | Officer | VP, Finance | 14 | 2014–2020 | |
| BARRIS PETER J | TenPercentOwner | 2 | 2015–2018 | ||
| BASKETT FOREST | TenPercentOwner | 2 | 2015–2018 | ||
| Florence Anthony A. Jr. | TenPercentOwner | 2 | 2015–2018 | ||
| Growth Equity Opportunities IV, LLC | TenPercentOwner | 2 | 2015–2018 | ||
| Hove Anders D | Director; TenPercentOwner | 7 | 2015–2024 | ||
| Koh Bong Y | TenPercentOwner | 4 | 2015–2025 | ||
| KOLLURI KRISHNA KITTU | TenPercentOwner | 1 | 2015 | person page Fuzzy | |
| MAKOWER JOSHUA | TenPercentOwner | 2 | 2015–2018 | ||
| MOTT DAVID M | TenPercentOwner | 2 | 2015–2018 | ||
| NEA 15 GP, LLC | TenPercentOwner | 2 | 2015–2018 | ||
| NEA Partners 15, L.P. | TenPercentOwner | 2 | 2015–2018 | ||
| New Enterprise Associates 15, L.P. | TenPercentOwner | 2 | 2015–2018 | ||
| Sakoda Jon | TenPercentOwner | 2 | 2015–2018 | ||
| SANDELL SCOTT D | TenPercentOwner | 2 | 2015–2018 | ||
| Sonsini Peter W. | TenPercentOwner | 2 | 2015–2018 | ||
| Venrock Healthcare Capital Partners II, L.P. | TenPercentOwner | 2 | 2015–2018 | ||
| VENROCK HEALTHCARE CAPITAL PARTNERS LP | TenPercentOwner | 2 | 2015–2018 | ||
| VHCP Co-Investment Holdings II, LLC | TenPercentOwner | 2 | 2015–2018 | ||
| VHCP Co-Investment Holdings, LLC | TenPercentOwner | 2 | 2015–2018 | ||
| VHCP Management II, LLC | TenPercentOwner | 2 | 2015–2018 | ||
| VHCP Management, LLC | TenPercentOwner | 2 | 2015–2018 | ||
| Viswanathan Ravi | TenPercentOwner | 2 | 2015–2018 | ||
| Weller Harry R | TenPercentOwner | 1 | 2015 | ||
| Shah Nimish P | TenPercentOwner | 3 | 2018–2025 | ||
| Dekker C. Jeffrey | Officer | Chief Financial Officer | 3 | 2021–2022 | |
| Funicular Fund, LP | Other | 15 | 2022 | ||
| Ma-Weaver Jacob | Director,TenPercentOwner,Other; Director,TenPercentOwnerOther; Other | 18 | 2022–2024 | ||
| Funicular Funds, LP | TenPercentOwnerOther | 3 | 2022 | ||
| Flynn James P | Director | 3 | 2022–2024 | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | TenPercentOwner | 4 | 2024 | ||
| JANUS HENDERSON GROUP PLC | TenPercentOwner | 4 | 2024 | ||
| Agarwal Arjun | Officer | Senior Vice President, Finance; SVP, Finance; SVP, Finance and Treasurer | 11 | 2024–2026 | |
| BALL KRISTINE M | Director | 3 | 2024–2026 | ||
| Dambkowski Carl | Director | 6 | 2024–2026 | ||
| Fairmount Funds Management LLC | Director,TenPercentOwner | 7 | 2024–2026 | ||
| Fairmount Healthcare Co-Invest III L.P. | Director; Director,TenPercentOwner | 5 | 2024–2026 | ||
| Fairmount Healthcare Fund II L.P. | Director,TenPercentOwner | 7 | 2024–2026 | ||
| Goncalves Joana | Officer | Chief Medical Officer | 13 | 2024–2026 | |
| Harwin Peter Evan | Director,TenPercentOwner | 7 | 2024–2026 | ||
| Kiselak Tomas | Director,TenPercentOwner | 7 | 2024–2026 | ||
| Klein Lawrence Otto | Director,Officer | Chief Executive Officer; President and CEO | 7 | 2024–2026 | |
| Kulkarni Samarth | Director | 3 | 2024–2026 | ||
| Quinlan Paul T | Officer | General Counsel; General Counsel and Secretary | 8 | 2024–2026 | |
| Turtle Cameron | Director | 2 | 2024–2025 | ||
| Venrock Healthcare Capital Partners EG, L.P. | TenPercentOwner | 2 | 2025 | ||
| Venrock Healthcare Capital Partners III, L.P. | TenPercentOwner | 2 | 2025 | ||
| VHCP Co-Investment Holdings III, LLC | TenPercentOwner | 2 | 2025 | ||
| VHCP Management EG, LLC | TenPercentOwner | 2 | 2025 | ||
| VHCP Management III, LLC | TenPercentOwner | 2 | 2025 | ||
| Sandler Laura Lee | Officer | Chief Operating Officer | 11 | 2025–2026 | |
| Martin Christopher Nathan | Director | 3 | 2025–2026 | ||
| Edwards Larry Todd | Officer | Chief Commercial Officer | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2015-06-25 | ARCA biopharma, Inc. | Pharmaceuticals | $51,650,404 | $51,650,404 | 14 | 1 |
| 2014-02-20 | ARCA biopharma, Inc. | Pharmaceuticals | $326,158 | $326,158 | 2 | 1 |
| 2012-01-05 | ARCA biopharma, Inc. | Pharmaceuticals | $4,549,285 | $4,549,285 | 6 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.